SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

Thyroid cancer incidence is increasing throughout the world. Although this appears to be due largely to enhanced detection of early thyroid cancers by the more generalised use of thyroid ultrasound ...

The US FDA’s approval is based on data from the ongoing Phase 2 PHAROS clinical trial (NCT03915951), an open-label, multicenter, single-arm study examining BRAFTOVI+MEKTOVI combination therapy in both ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

Researchers have discovered a signaling pathway between cytokines and BRAF that promotes tumor growth. The finding could provide a potential therapeutic target. The protein BRAF is a key player in the ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...

The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) gained approval from the Food and Drug Administration (FDA) for the treatment of patients with BRAF V600–positive advanced or ...

Please provide your email address to receive an email when new articles are posted on . The triplet combination of vemurafenib/cobimetinib/atezolizumab showed ...

Results from the Phase II PHAROS trial found that treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer administered Braftovi in combination with Mektovi achieved an ...

Anticancer drug resistance remains a crucial impediment to the care of many patients with cancer. Although the exact mechanisms of resistance may differ for each therapy, common mechanisms of ...